





Figure 2

General features of response




Figure 3






Figure 4A








Figure 6




Figure 7




Figure 8




Figure 9




Figure 10





Figure 11A

Low dose Anti-LHRH
N = 3 Rats, Dosed at 0 and 3 Weeks



Solid lines = Titers
Dashed lines = Testosterone

Figure 11B

Higher dose Anti-LHRH
N = 3 Rats, Dosed at 0 and 9 Weeks




Figure 12





Figure 13A

Original Anti-IgE Formulation: 27 Week-Titers

Macaques




~27.5 weeks to basal line

Figure 13B

New Anti-IgE Formulation: 54-Week Titers

Macaques




~54 weeks to basal line

Figure 14A

Original Anti-LHRH Formulation

N = 8 Pigs Per Group, Dosed at 0 and 8 Weeks

Levers
• UB1H1 immunogen
• Adjuvant




Solid lines = Titers
Dashed lines = Testosterone

Figure 14B

New Anti-LHRH Formulation

N = 8 Pigs Per Group, Dosed at 0 and 8 Weeks



18+ week efficacy
(testosterone remains below
desired threshold, pigs remain
immunosuppressed)

Figure 15
UBITh Responsive T cells Can Be Detected in Naïve PBMC of Normal Blood Donors




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21

